Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Biogen Idec Stories

2013-12-05 23:04:28

Reportbuyer.com just published a new market research report: Drug Delivery Partnering Terms and Agreements. London (PRWEB) December 05, 2013 The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals....

2013-12-03 08:33:43

SCOTTSDALE, Ariz., Dec. 3, 2013 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based, commercial-stage pharmaceutical company focused on prescription Medical Foods, today announced the election of Francesco Granata, M.D., to its Board of Directors. Dr. Granata is currently Executive in Residence at Warburg Pincus, a leading private equity firm focused on growth investing. He is an accomplished healthcare executive with more than 35 years of experience in the...

2013-11-30 23:03:24

MarketReportsOnline.com offers “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)” research that analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Dallas, Texas (PRWEB) November 30, 2013 The report titled "Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)" provide an insight into the market dynamics and various trends and opportunities associated...

2013-11-25 12:27:25

More Neurologists Now Mention Once-Daily Dosing As Aubagio's Biggest Advantage Compared With Earlier in Launch, According to a New Report from BioTrends Research Group EXTON, Pa., Nov. 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. neurologists have prescribed Genzyme's Aubagio, the second oral disease-modifying therapy (DMT) to reach the...

2013-11-22 08:23:05

CARLSBAD, Calif., Nov. 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it plans to add a 12 mg cohort to the ongoing Phase 1b/2a study evaluating ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA). In addition, a 12 mg dose will be included in an open-label extension study for those children who have completed dosing in previous studies. The addition of the 12 mg cohort will allow for the investigation of this dose in support of the...

2013-11-20 08:28:35

LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated initial progress in its research collaboration with Biogen Idec, M.A. ("Biogen Idec") to discover microRNAs as biomarkers for multiple sclerosis ("MS") and has received a milestone payment. Regulus has developed a highly reproducible, proprietary...

2013-11-20 08:26:22

Nevertheless, Injectables Remain First-Line Mainstays Among Newly Diagnosed Patients, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through examination of U.S. patient-level claims data, total patient share of platform injectable disease-modifying therapies (DMTs) among recently treated multiple sclerosis...

2013-11-14 23:04:03

Reportbuyer.com just published a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules. London (PRWEB) November 14, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of...

2013-11-12 08:34:13

CARLSBAD, Calif., Nov. 12, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1.5 million milestone payment from Biogen Idec related to the advancement of the ongoing Phase 2 study of ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA). (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) The Phase 2 study of ISIS-SMN(Rx) is an open-label, multiple-dose, dose-escalation pilot study in infants who have been diagnosed...

2013-11-05 08:35:12

-Improved 2013 financial guidance CARLSBAD, Calif., Nov. 5, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported a pro forma net operating loss (NOL) of $22.7 million and $23.5 million for the three and nine months ended September 30, 2013, respectively, compared to a pro forma NOL of $26.0 million and $36.0 million for the same periods in 2012. On a GAAP basis, Isis reported a loss from operations of $25.5 million and $31.8 million for the three and nine months...